Clinical Trials Logo

Muscle Invasive Bladder Cancer clinical trials

View clinical trials related to Muscle Invasive Bladder Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03397394 Terminated - Bladder Cancer Clinical Trials

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

ATLAS
Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

NCT ID: NCT03234153 Terminated - Clinical trials for Muscle-invasive Bladder Cancer

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

NITIMIB
Start date: July 15, 2018
Phase: Phase 2
Study type: Interventional

The trial assess the safety and antitumor activity of the anti-PD-L1 antibody Durvalumab in combination with the anti-CTLA4 antibody Tremelimumab.

NCT ID: NCT02716896 Terminated - Clinical trials for Muscle Invasive Bladder Cancer

Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer

Start date: May 2016
Phase: N/A
Study type: Interventional

Currently the standard treatment of muscle invasive bladder cancer is the complete removal of bladder and adjacent organs, such as prostate or ovaries. Radical cystectomy is fraught with complications and risk of death. The researchers hope to learn if chemoradiation (i.e. using chemotherapy and radiation), also an acceptable treatment for muscle invasive bladder cancer, can be used a good alternative therapy option.